172 related articles for article (PubMed ID: 34465005)
1. 'For me, it didn't seem as drastic a step as being controlled by insulin': A qualitative investigation of expectations and experiences of non-insulin injectable therapy among adults with type 2 diabetes.
Holmes-Truscott E; Schipp J; Dunning T; Furler J; Hagger V; Holloway EE; Manski-Nankervis JA; Shaw JE; Skinner T; Speight J
Diabet Med; 2022 Feb; 39(2):e14681. PubMed ID: 34465005
[TBL] [Abstract][Full Text] [Related]
2. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
4. Use of an Electronic Medical Record (EMR) to Identify Glycemic Intensification Strategies in Type 2 Diabetes.
Korytkowski MT; Brooks M; Lombardero M; DeAlmeida D; Kanter J; Magaji V; Orchard T; Siminerio L
J Diabetes Sci Technol; 2015 May; 9(3):593-601. PubMed ID: 25526759
[TBL] [Abstract][Full Text] [Related]
5. Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.
Weeda ER; Muraoka AK; Brock MD; Cannon JM
Int J Clin Pract; 2021 Sep; 75(9):e14060. PubMed ID: 33527605
[TBL] [Abstract][Full Text] [Related]
6. Real-world use of glucagon-like peptide-1 receptor agonists in youth with type 2 diabetes is associated with short-term improvements in HbA1c.
Samuels SL; Chajecki A; Hu P; Kayser M; Weyman K; Pan B; Brown EA; Van Name M; Wolf RM
Diabetes Obes Metab; 2024 Apr; 26(4):1305-1313. PubMed ID: 38229444
[TBL] [Abstract][Full Text] [Related]
7. Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy.
Fadini GP; Frison V; Rigato M; Morieri ML; Simioni N; Tadiotto F; D'Ambrosio M; Paccagnella A; Lapolla A; Avogaro A
Acta Diabetol; 2020 Mar; 57(3):367-375. PubMed ID: 31673896
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain.
Conget I; Mauricio D; Ortega R; Detournay B;
BMJ Open; 2016 Jul; 6(7):e010197. PubMed ID: 27466235
[TBL] [Abstract][Full Text] [Related]
9. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Triplitt C; Solis-Herrera C
Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features.
Lyseng-Williamson KA
Clin Drug Investig; 2019 Aug; 39(8):805-819. PubMed ID: 31317516
[TBL] [Abstract][Full Text] [Related]
12. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
Brunton SA; Wysham CH
Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
[TBL] [Abstract][Full Text] [Related]
13. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
[TBL] [Abstract][Full Text] [Related]
14. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
[TBL] [Abstract][Full Text] [Related]
15. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Madsbad S
Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
[TBL] [Abstract][Full Text] [Related]
16. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study.
Morieri ML; Rigato M; Frison V; Simioni N; D'Ambrosio M; Tadiotto F; Paccagnella A; Lapolla A; Avogaro A; Fadini GP
Diabetes Obes Metab; 2019 Nov; 21(11):2542-2552. PubMed ID: 31364233
[TBL] [Abstract][Full Text] [Related]
17. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
Montvida O; Klein K; Kumar S; Khunti K; Paul SK
Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
[TBL] [Abstract][Full Text] [Related]
18. Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus.
Rydén A; Chen S; Flood E; Romero B; Grandy S
Patient; 2017 Aug; 10(4):475-487. PubMed ID: 28315192
[TBL] [Abstract][Full Text] [Related]
19. IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.
Hughes E
Prim Care Diabetes; 2016 Jun; 10(3):202-9. PubMed ID: 26776758
[TBL] [Abstract][Full Text] [Related]
20. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump.
Cohen O; Filetti S; Castañeda J; Maranghi M; Glandt M
Diabetes Care; 2016 Aug; 39 Suppl 2():S180-6. PubMed ID: 27440831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
